share_log
Benzinga ·  06/20 08:56

Kyverna Therapeutics Shares Are Trading Higher After the Company Announced KYV-101 Received FDA IND Clearance for the Treatment of Patients With Treatment-refractory Stiff-Person Syndrome in the KYSA-8 Phase 2 Trial

Kyverna Therapeutics股票正在高价交易,该公司宣布KYV-101已获得FDA IND许可,用于治疗KYSA-8第2阶段试验中的治疗耐药性强的Stiff-Person综合症患者

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发